Upregulation of collagen type X alpha 1 promotes the progress of triple-negative breast cancer via Wnt/β-catenin signaling.
COL10A1
EMT
TNBC
angiogenesis
migration
proliferation
Journal
Molecular carcinogenesis
ISSN: 1098-2744
Titre abrégé: Mol Carcinog
Pays: United States
ID NLM: 8811105
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
revised:
04
04
2024
received:
29
11
2023
accepted:
07
05
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
Triple-negative breast cancer (TNBC) is a malignant tumor with high degree of malignancy and lack of effective target treatment. The research aims to explore the role and mechanism of X collagen alpha-1 chain protein (COL10A1 gene) in TNBC. UALCAN and Kaplan-Meier were used to detect the expression of COL10A1 and its role in the prognosis of breast cancer patients. The cells with stably expressing high levels of COL10A1 were obtained by recombinant lentivirus infection. The expression of COL10A1 in cells was temporarily downregulated by siRNA interference fragments. Real-time quantitative polymerase chain reaction and western blot analysis were utilized to detect the changes of COL10A1 mRNA and protein expression. The biological functions of the cells were evaluated by colony formation, cell counting kit-8, cell invasion and wound healing experiments. In addition, the effect of COL10A1 on angiogenesis was investigated by tube formation assay. Xenograft tumor model was used to confirm the effect of COL10A1 on tumorigenicity in vivo and multiplex fluorescent immunohistochemistry to detect multiple proteins simultaneously. The possible molecular mechanism of the function of COL10A1 was speculated through the detection of proteins in functionally related pathways. COL10A1 is highly expressed and is significantly associated with worse overall survival (OS) and recurrence-free survival (RFS) in TNBC. Overexpression of COL10A1 increased the clone formation rate and cell migration capacity of TNBC cells. In the COL10A1 overexpression group, the clone formation rates of MD-MB-231 and BT-549 cells (21.5 ± 0.62, 27.83 ± 3.72)% were significantly higher than those in the control group(15.23 ± 2.79, 19.4 ± 1.47)%, and the relative migration ratio (47.40 ± 3.09, 41.26 ± 4.33)% were higher than those in the control group (34.48 ± 2.03, 21.80 ± 1.03)%. When the expression of COL10A1 was downregulated, the ability of clone formation and wound-healing migration capacity in TNBC cells was weakened. Upregulated COL10A1 in TNBC cells generated more junctions and longer total segments between vascular endothelial cells, and promoted angiogenesis of the cells, and thus enhanced the tumorigenesis. In TNBC, it was found that COL10A1 might affect epithelial-mesenchymal transition (EMT) of the cells through Wnt/β-catenin signaling pathway by the detection of the related pathway proteins. COL10A1 is highly expressed in TNBC, and its high expression leads to poor OS and RFS. COL10A1 may enhance TNBC cell proliferation, migration and tumor-related angiogenesis, and promote tumorigenesis in vivo via Wnt/β-catenin signaling.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Natural Science Foundation of Shandong Province
ID : ZR2021MH158
Organisme : Natural Science Foundation of Shandong Province
ID : ZR2021MH119
Organisme : National Natural Science Foundation of China
ID : 81572616
Organisme : National Natural Science Foundation of China
ID : 81772845
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population‐based study (CONCORD). Lancet Oncol. 2008;9(8):730‐756. doi:10.1016/s1470-2045(08)70179-7
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249. doi:10.3322/caac.21660
Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15‐23. doi:10.1016/j.breast.2022.08.010
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241‐256. doi:10.5858/arpa.2013-0953-SA
Van Meter EN, Onyango JA, Teske KA. A review of currently identified small molecule modulators of microRNA function. Eur J Med Chem. 2020;188:112008. doi:10.1016/j.ejmech.2019.112008
Cheang MCU, Voduc D, Bajdik C, et al. Basal‐like breast cancer defined by five biomarkers has superior prognostic value than triple‐negative phenotype. Clin Cancer Res. 2008;14(5):1368‐1376. doi:10.1158/1078-0432.Ccr-07-1658
Emens LA, Cruz C, Eder JP, et al. Long‐term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple‐negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74‐82. doi:10.1001/jamaoncol.2018.4224
Zhang X, Liang H, Liu W, Li X, Zhang W, Shang X. A novel sequence variant in COL10A1 causing spondylometaphyseal dysplasia accompanied with coxa valga: a case report. Medicine. 2019;98(30):e16485. doi:10.1097/md.0000000000016485
Chapman KB, Prendes MJ, Sternberg H, et al. COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature. Future Oncol. 2012;8(8):1031‐1040. doi:10.2217/fon.12.79
Li T, Huang H, Shi G, et al. TGF‐β1‐SOX9 axis‐inducible COL10A1 promotes invasion and metastasis in gastric cancer via epithelial‐to‐mesenchymal transition. Cell Death Dis. 2018;9(9):849. doi:10.1038/s41419-018-0877-2
Chen S, Wei Y, Liu H, et al. Analysis of Collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics. Bioengineered. 2021;12(1):127‐137. doi:10.1080/21655979.2020.1864912
Huang H, Li T, Ye G, et al. High expression of COL10A1 is associated with poor prognosis in colorectal cancer. Onco Targets Ther. 2018;11:1571‐1581. doi:10.2147/ott.S160196
Wen Z, Sun J, Luo J, et al. COL10A1‐DDR2 axis promotes the progression of pancreatic cancer by regulating MEK/ERK signal transduction. Front Oncol. 2022;12:1049345. doi:10.3389/fonc.2022.1049345
Zhang M, Chen H, Wang M, Bai F, Wu K. Bioinformatics analysis of prognostic significance of COL10A1 in breast cancer. Biosci Rep. 2020;40(2):BSR20193286. doi:10.1042/bsr20193286
Zhou W, Li Y, Gu D, et al. High expression COL10A1 promotes breast cancer progression and predicts poor prognosis. Heliyon. 2022;8(10):e11083. doi:10.1016/j.heliyon.2022.e11083
Baek JM, Chae BJ, Song BJ, Jung SS. The potential role of estrogen receptor β2 in breast cancer. Int J Surg. 2015;14:17‐22. doi:10.1016/j.ijsu.2014.10.007
Zu C, Zhang M, Xue H, et al. Emodin induces apoptosis of human breast cancer cells by modulating the expression of apoptosis‐related genes. Oncol Lett. 2015;10(5):2919‐2924. doi:10.3892/ol.2015.3646
Zu C, Qin G, Yang C, et al. Low dose Emodin induces tumor senescence for boosting breast cancer chemotherapy via silencing NRARP. Biochem Biophys Res Commun. 2018;505(4):973‐978. doi:10.1016/j.bbrc.2018.09.045
Tanner LTA, Cheung KL. Correlation between breast cancer and lifestyle within the Gulf Cooperation Council countries: a systematic review. World J Clin Oncol. 2020;12(4):217‐242. doi:10.5306/wjco.v11.i4.217
Jolly LA, Novitskiy S, Owens P, et al. Fibroblast‐Mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss. Cancer Res. 2016;76(7):1804‐1813. doi:10.1158/0008-5472.Can-15-2351
Xu S, Xu H, Wang W, et al. The role of collagen in cancer: from bench to bedside. J Transl Med. 2019;17(1):309. doi:10.1186/s12967-019-2058-1
Ren T, Zhang J, Zhang J, Liu X, Yao L. Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients. Med Oncol. 2013;30(1):397. doi:10.1007/s12032-012-0397-3
Kielty CM, Kwan APL, Holmes DF, Schor SL, Grant ME. Type X collagen, a product of hypertrophic chondrocytes. Biochem J. 1985;227(2):545‐554. doi:10.1042/bj2270545
Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012;31(1‐2):295‐321. doi:10.1007/s10555-012-9346-z
Elkamhawy A, Lu Q, Nada H, Woo J, Quan G, Lee K. The journey of DDR1 and DDR2 kinase inhibitors as rising stars in the fight against cancer. Int J Mol Sci. 2021;22(12):6535. doi:10.3390/ijms22126535
Liang Y, Xia W, Zhang T, et al. Upregulated collagen COL10A1 remodels the extracellular matrix and promotes malignant progression in lung adenocarcinoma. Front Oncol. 2020;10:573534. doi:10.3389/fonc.2020.573534
Karagoz K, Lehman HL, Stairs DB, Sinha R, Arga KY. Proteomic and metabolic signatures of esophageal squamous cell carcinoma. Current Cancer Drug Targets. Published online 2016 February 2, 2016.
Wang X, Bai Y, Zhang F, et al. Prognostic value of COL10A1 and its correlation with tumor‐infiltrating immune cells in urothelial bladder cancer: a comprehensive study based on bioinformatics and clinical analysis validation. Front Immunol. 2023;14:955949. doi:10.3389/fimmu.2023.955949
Solé X, Crous‐Bou M, Cordero D, et al. Discovery and validation of new potential biomarkers for early detection of colon cancer. PLoS One. 2014;9(9):e106748. doi:10.1371/journal.pone.0106748
Giussani M, Landoni E, Merlino G, et al. Extracellular matrix proteins as diagnostic markers of breast carcinoma. J Cell Physiol. 2018;233(8):6280‐6290. doi:10.1002/jcp.26513
Nusse R, Clevers H. Wnt/β‐catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985‐999. doi:10.1016/j.cell.2017.05.016
Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461‐1473. doi:10.1038/onc.2016.304
Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/β‐catenin activation promotes prostate tumor progression in a mouse model. Oncogene. 2011;30(16):1868‐1879. doi:10.1038/onc.2010.560
Vilchez V. Targeting Wnt/β‐catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 2016;22(2):823‐832. doi:10.3748/wjg.v22.i2.823
Zhou P, Li Y, Li B, et al. NMIIA promotes tumor growth and metastasis by activating the Wnt/β‐catenin signaling pathway and EMT in pancreatic cancer. Oncogene. 2019;38(27):5500‐5515. doi:10.1038/s41388-019-0806-6
Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020;19(1):165. doi:10.1186/s12943-020-01276-5